Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, Rohit; Noureddin, Mazen; V. Kowdley, Kris; Kohli, Anita; Sheikh, Aasim; Neff, Guy; Raj Bhandari, Bal; Gunn, Nadege; H. Caldwell, Stephen; Goodman, Zachary; Wapinski, Ilan; B. Resnick, Murray; H. Beck, Andrew; Ding, Dora; Jia, Catherine; Chuang, Jen‐Chieh; S. Huss, Ryan; Chung, Chuhan; Mani Subramanian, G.; P. Myers, Robert; Patel, Keyur; B. Borg, Brian; Ghalib, Reem; Kabler, Heidi; Poulos, John; Younes, Ziad; Elkhashab, Magdy; Hassanein, Tarek; Iyer, Rajalakshmi; Ruane, Peter; L. Shiffman, Mitchell; I. Strasser, Simone; Wai‐Sun Wong, Vincent; Alkhouri, Naim; the ATLAS Investigators, for

doi:10.1002/hep.31622

Public

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Published in Hepatology • Nov 10, 2020

Authors:

Rohit Loomba

Mazen Noureddin

Kris V. Kowdley

Abstract

BACKGROUND AND AIMS: Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease. APPROACH AND RESULTS: In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3-F4) were randomized to receive placebo, selonsertib 18 mg, cilofexor 30 mg, or fir...

Subject

Cirrhosis

Medicine

Gastroenterology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!